Indications and recommendations for the use of recombinant human growth hormone in adult short bowel syndrome patients dependent on parenteral nutrition

Ezra Steiger, John K. DiBaise, Bernard Messing, Laura E. Matarese, Sandra Blethen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Given the lack of published guidelines regarding the use of trophic factors to treat patients with short bowel syndrome (SBS), a group of experts in the field convened to discuss best-practice strategies. Trophic factors, such as recombinant human growth hormone (r-hGH) and glucagon-like peptide-2 (GLP-2), may enhance intestinal adaptation and decrease parenteral nutrition (PN) requirements; therefore, their utility in treating SBS patients was evaluated. Available clinical data on use of r-hGH therapy in SBS patients were discussed, as were the utility of r-hGH in the PN weaning process, the optimal timing of r-hGH therapy, and how to select appropriate patients for r-hGH therapy. In addition, contraindications and precautions as well as adverse effects of r-hGH treatment were discussed. The meeting culminated with the development of a treatment algorithm to summarize best-practice recommendations for the management of SBS in adult patients. This algorithm involves attempting to wean patients off PN without the use of trophic factors. If this is unsuccessful, it is recommended that patients be treated with an r-hGH regimen or participate in investigational studies using other trophic factors.

Original languageEnglish (US)
JournalJournal of Clinical Gastroenterology
Volume40
Issue numberSUPPL. 2
DOIs
StatePublished - May 2006

Fingerprint

Short Bowel Syndrome
Human Growth Hormone
Parenteral Nutrition
Growth Hormone
Practice Guidelines
Nutritional Physiological Phenomena
Glucagon-Like Peptide 2
Therapeutics
Nutritional Requirements
Practice Management
Weaning
Guidelines

Keywords

  • Management
  • Recombinant growth hormone
  • Short bowel syndrome
  • Trophic factors

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Indications and recommendations for the use of recombinant human growth hormone in adult short bowel syndrome patients dependent on parenteral nutrition. / Steiger, Ezra; DiBaise, John K.; Messing, Bernard; Matarese, Laura E.; Blethen, Sandra.

In: Journal of Clinical Gastroenterology, Vol. 40, No. SUPPL. 2, 05.2006.

Research output: Contribution to journalArticle

Steiger, Ezra ; DiBaise, John K. ; Messing, Bernard ; Matarese, Laura E. ; Blethen, Sandra. / Indications and recommendations for the use of recombinant human growth hormone in adult short bowel syndrome patients dependent on parenteral nutrition. In: Journal of Clinical Gastroenterology. 2006 ; Vol. 40, No. SUPPL. 2.
@article{77f425c0de434c9da446081c24bb2a61,
title = "Indications and recommendations for the use of recombinant human growth hormone in adult short bowel syndrome patients dependent on parenteral nutrition",
abstract = "Given the lack of published guidelines regarding the use of trophic factors to treat patients with short bowel syndrome (SBS), a group of experts in the field convened to discuss best-practice strategies. Trophic factors, such as recombinant human growth hormone (r-hGH) and glucagon-like peptide-2 (GLP-2), may enhance intestinal adaptation and decrease parenteral nutrition (PN) requirements; therefore, their utility in treating SBS patients was evaluated. Available clinical data on use of r-hGH therapy in SBS patients were discussed, as were the utility of r-hGH in the PN weaning process, the optimal timing of r-hGH therapy, and how to select appropriate patients for r-hGH therapy. In addition, contraindications and precautions as well as adverse effects of r-hGH treatment were discussed. The meeting culminated with the development of a treatment algorithm to summarize best-practice recommendations for the management of SBS in adult patients. This algorithm involves attempting to wean patients off PN without the use of trophic factors. If this is unsuccessful, it is recommended that patients be treated with an r-hGH regimen or participate in investigational studies using other trophic factors.",
keywords = "Management, Recombinant growth hormone, Short bowel syndrome, Trophic factors",
author = "Ezra Steiger and DiBaise, {John K.} and Bernard Messing and Matarese, {Laura E.} and Sandra Blethen",
year = "2006",
month = "5",
doi = "10.1097/01.mcg.0000212680.52290.02",
language = "English (US)",
volume = "40",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Indications and recommendations for the use of recombinant human growth hormone in adult short bowel syndrome patients dependent on parenteral nutrition

AU - Steiger, Ezra

AU - DiBaise, John K.

AU - Messing, Bernard

AU - Matarese, Laura E.

AU - Blethen, Sandra

PY - 2006/5

Y1 - 2006/5

N2 - Given the lack of published guidelines regarding the use of trophic factors to treat patients with short bowel syndrome (SBS), a group of experts in the field convened to discuss best-practice strategies. Trophic factors, such as recombinant human growth hormone (r-hGH) and glucagon-like peptide-2 (GLP-2), may enhance intestinal adaptation and decrease parenteral nutrition (PN) requirements; therefore, their utility in treating SBS patients was evaluated. Available clinical data on use of r-hGH therapy in SBS patients were discussed, as were the utility of r-hGH in the PN weaning process, the optimal timing of r-hGH therapy, and how to select appropriate patients for r-hGH therapy. In addition, contraindications and precautions as well as adverse effects of r-hGH treatment were discussed. The meeting culminated with the development of a treatment algorithm to summarize best-practice recommendations for the management of SBS in adult patients. This algorithm involves attempting to wean patients off PN without the use of trophic factors. If this is unsuccessful, it is recommended that patients be treated with an r-hGH regimen or participate in investigational studies using other trophic factors.

AB - Given the lack of published guidelines regarding the use of trophic factors to treat patients with short bowel syndrome (SBS), a group of experts in the field convened to discuss best-practice strategies. Trophic factors, such as recombinant human growth hormone (r-hGH) and glucagon-like peptide-2 (GLP-2), may enhance intestinal adaptation and decrease parenteral nutrition (PN) requirements; therefore, their utility in treating SBS patients was evaluated. Available clinical data on use of r-hGH therapy in SBS patients were discussed, as were the utility of r-hGH in the PN weaning process, the optimal timing of r-hGH therapy, and how to select appropriate patients for r-hGH therapy. In addition, contraindications and precautions as well as adverse effects of r-hGH treatment were discussed. The meeting culminated with the development of a treatment algorithm to summarize best-practice recommendations for the management of SBS in adult patients. This algorithm involves attempting to wean patients off PN without the use of trophic factors. If this is unsuccessful, it is recommended that patients be treated with an r-hGH regimen or participate in investigational studies using other trophic factors.

KW - Management

KW - Recombinant growth hormone

KW - Short bowel syndrome

KW - Trophic factors

UR - http://www.scopus.com/inward/record.url?scp=33745297406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745297406&partnerID=8YFLogxK

U2 - 10.1097/01.mcg.0000212680.52290.02

DO - 10.1097/01.mcg.0000212680.52290.02

M3 - Article

C2 - 16770169

AN - SCOPUS:33745297406

VL - 40

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - SUPPL. 2

ER -